Sustained Release of FGF-21 from a Genetically Engineered Injectable Depot for the Treatment of Type 2 Diabetes

被引：0
|
作者：
Gilroy, Caslin A.
Chilkoti, Ashutosh
机构：
来源：
DIABETES | 2017年 / 66卷
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1092-P
引用
收藏
页码：A289 / A289
页数：1
相关论文
共 50 条
  • [41] Evaluation of concentrations of FGF-21-a new adipocytokine in type 2 diabetes
    Matuszek, Beata
    Lenart-Lipinska, Monika
    Duma, Dariusz
    Solski, Janusz
    Nowakowski, Andrzej
    ENDOKRYNOLOGIA POLSKA, 2010, 61 (01) : 50 - 54
  • [42] Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model
    Shao, Minglong
    Yu, Lechu
    Zhang, Fangfang
    Lu, Xuemian
    Li, Xiaokun
    Cheng, Peng
    Lin, Xiufei
    He, Luqing
    Jin, Shunzi
    Tan, Yi
    Yang, Hong
    Zhang, Chi
    Cai, Lu
    AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2015, 309 (01): : E45 - E54
  • [43] Development of 1 Month Sustained-Release Microspheres Containing Liraglutide for Type 2 Diabetes Treatment
    Gao, Zejing
    Wei, Yi
    Ge, Jia
    Liu, Jingxuan
    Qin, Ying
    Gong, Fangling
    Ma, Guanghui
    ACS APPLIED MATERIALS & INTERFACES, 2024, 16 (20) : 25869 - 25878
  • [44] Two-Layer Sustained-Release Microneedles Encapsulating Exenatide for Type 2 Diabetes Treatment
    Liu, Han
    Zhang, Suohui
    Zhou, Zequan
    Xing, Mengzhen
    Gao, Yunhua
    PHARMACEUTICS, 2022, 14 (06)
  • [45] GASTRIC BYPASS INCREASES FGF-19 AND FGF-21 AND IMPROVES STEATOHEPATITIS IN METABOLICALLY SICK PATIENTS WITH DIABETES MELLITUS TYPE 2 AND LOW-BMI <35KG/M2
    Mueller-Stich, B. P.
    Billeter, A. T.
    Straub, B. K.
    Israel, B.
    Schulte, T.
    Schirmacher, P. P.
    Buechler, M. W.
    Nawroth, P. P.
    OBESITY SURGERY, 2016, 26 : S88 - S88
  • [46] New Injectable Agents for the Treatment of Type 2 Diabetes Part 1-Injectable Insulins
    George, Christa M.
    Byun, AhYoung
    Howard-Thompson, Amanda
    AMERICAN JOURNAL OF MEDICINE, 2018, 131 (07): : 752 - 754
  • [47] Addressing Unmet Needs With Injectable Medications in Type 2 Diabetes Treatment
    不详
    JOURNAL OF FAMILY PRACTICE, 2017, 66 (10):
  • [48] Resistance training attenuates circulating FGF-21 and myostatin and improves insulin resistance in elderly men with and without type 2 diabetes mellitus: A randomised controlled clinical trial
    Shabkhiz, Fatemeh
    Khalafi, Mousa
    Rosenkranz, Sara
    Karimi, Pouran
    Moghadami, Kamilia
    EUROPEAN JOURNAL OF SPORT SCIENCE, 2021, 21 (04) : 636 - 645
  • [49] Engineered Skeletal Muscle Constructs For Type 2 Diabetes Treatment
    Beckerman, M.
    Safina, D.
    Shoyhat, H.
    Bachinsky, Y.
    Karnieli, E.
    Bilan, P. J.
    Lewis, E. C.
    Levenberg, S.
    TISSUE ENGINEERING PART A, 2022, 28 : 406 - 407
  • [50] Sustained Release of Exendin 4 Using Injectable and lonic-Nano-Complex Forming Polymer Hydrogel System for Long-Term Treatment of Type 2 Diabetes Mellitus
    Seo, Bo-Bae
    Park, Mi-Ran
    Song, Soo-Chang
    ACS APPLIED MATERIALS & INTERFACES, 2019, 11 (17) : 15201 - 15211
12345